ACEI/ARB use among high risk patients with coronary heart disease in China: a cross-sectional study
10.3760/cma.j.issn.0253-3758.2013.01.005
- VernacularTitle:高危冠心病患者血管紧张素转换酶抑制剂类药物应用现况调查
- Author:
Jia-Min LIU
1
;
Lei GE
;
Jing LI
;
Xi LI
;
Fang FENG
;
Hai-Bo ZHANG
;
Yan GAO
;
Xin PANG
;
Yi-Ping CHEN
;
Zheng-Ming CHEN
;
Martin LANDRAY
;
Jane ARMITAGE
;
Fang CHEN
;
Li-Xin JIANG
Author Information
1. 100037,中国医学科学院北京协和医学院国家心血管病中心阜外心血管病医院心血管疾病国家重点实验室中国牛津国际医学研究中心
- Keywords:
Coronary disease;
Treatment outcome;
Cross-sectional study
- From:
Chinese Journal of Cardiology
2013;41(1):18-22
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study investigated current use of ACEI/ARB among high risk patients with coronary heart disease (CHD) in China and factors affecting ACEI/ARB use in these patients.Methods This cross-sectional survey was performed between June to December 2007 and May to November 2009 in 51hospitals from 14 cities.The characteristics of patients with established CHD were collected by electronic questionnaire.Results Only 45.8％ high risk CHD patients were taking ACEI/ARB and the ACEI/ARB medication decreased significantly with time after initial CHD diagnosis.ACEI/ARB was taken in 46.1％CHD patients complicated with diabetes mellitus and in 56.3％ CHD patients complicated with hypertension.Logistic regression analysis showed that comorbid hypertension was the strongest factor associated with ACEI/ARB use.In addition,male gender,history of myocardial infarction (MI),PCI and the time after initial CHD diagnosis were independent factors affecting the use of ACEI/ARB.Captopril was the most commonly prescribed ACEI in this cohort.Conclusion ACEI/ARB is underused in secondary prevention among high risk CHD patients in China.It remains a major challenge for healthcare professionals and policy makers tn make efforts on narrowing the gap between evidence and practice.
